中国药物经济学2019，Vol.14Issue(1)：101-106,6.DOI:10.12010/j.issn.1673-5846.2019.01.027
政策干预与医药上市公司创新绩效的关联性分析
Relevance Analysis of Policy Intervention and Innovation Performance of Pharmaceutical Listed Companies
摘要
Abstract
With the improvement of people's living standard and the emphasis on health, the pharmaceutical industry has attracted more and more attention. As a typical knowledge-intensive industry, pharmaceutical enterprises need to constantly research and develop new products to meet market demand. However, due to the long cycle and high risk of drug research and development, many pharmaceutical enterprises tend to produce generic drugs and reduce investment in research and development (R&D) for seeking profits, which leads to a great increase in the independent innovation ability of Chinese pharmaceutical enterprises. At present, the R&D capability of Chinese pharmaceutical industry has been generally strengthened, and the policy of pharmaceutical industry has made a great contribution to encouraging R&D capability. However, in recent years, it is still unstable and showing a downward trend. At the same time, the government support intervention has a positive correlation with the innovation performance of pharmaceutical listed enterprises.关键词
政策干预/医药上市公司/创新绩效/关联性Key words
Policy intervention/Pharmaceutical Listed Companies/Innovation performance/Relevance分类
医药卫生引用本文复制引用
胡美洁..政策干预与医药上市公司创新绩效的关联性分析[J].中国药物经济学,2019,14(1):101-106,6.
